Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 14/20 | 0.45 |
| ▸ | CCKAR | P32238 | 13/20 | 0.45 |
| ▸ | NOTCH1 | P46531 | 3/20 | 0.44 |
| ▸ | RBPJ | Q06330 | 2/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13904804 | 1.00 | CCKBR (0.45) | CCKBRCCKARNOTCH1RBPJPSEN1 | |
| SCHEMBL13904805 | 0.90 | NOTCH1 (0.45) | CCKBRCCKARNOTCH1RBPJPSEN1 | |
| SCHEMBL4151394 | 0.90 | NOTCH1 (0.45) | CCKBRCCKARNOTCH1RBPJPSEN1 | |
| SCHEMBL4147285 | 0.90 | NOTCH1 (0.44) | CCKBRCCKARNOTCH1RBPJPSEN1 | |
| SCHEMBL13904798 | 0.90 | NOTCH1 (0.44) | CCKBRCCKARNOTCH1RBPJPSEN1 | |
| SCHEMBL13904802 | 0.90 | NOTCH1 (0.44) | CCKBRCCKARNOTCH1RBPJPSEN1 | |
| SCHEMBL4168244 | 0.80 | NOTCH1 (0.65) | CCKBRNOTCH1RBPJPSEN1PSEN2 | |
| SCHEMBL4159022 | 0.80 | NOTCH1 (0.65) | CCKBRNOTCH1RBPJPSEN1PSEN2 | |
| SCHEMBL13904669 | 0.80 | NOTCH1 (0.65) | CCKBRNOTCH1RBPJPSEN1PSEN2 | |
| SCHEMBL13904657 | 0.80 | NOTCH1 (0.65) | CCKBRNOTCH1RBPJPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | claimed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | claimed |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-06-26 | — | — | US | claimed |
| US-6509333-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-21 | — | — | US | claimed |
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-26 | — | — | US | claimed |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20050261274-A1 | Lactams substituted by cyclic succinates as inhibitors of Abeta protein production | OLSON RICHARD E | 2005-11-24 | — | — | US | disclosed |
| US-6958329-B2 | Lactams substituted by cyclic succinates as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-06-26 | — | — | US | disclosed |
| US-6509333-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-21 | — | — | US | disclosed |
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | APP, BACE1, APH1A | CCKBR 2920/4885CCKAR 3521/4885NOTCH1 323/4885 |
| US-20050261274-A1 | Lactams substituted by cyclic succinates as inhibitors of Abeta protein production | BACE1, APP, APH1A | CCKBR 2683/4885CCKAR 3806/4885NOTCH1 166/4885 |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BACE1, APP, APH1A | CCKBR 2683/4885CCKAR 3806/4885NOTCH1 166/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | CCKBR 2885/4885CCKAR 3721/4885NOTCH1 488/4885 |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | APH1A, APH1B, APP | CCKBR 2831/4885CCKAR 3449/4885NOTCH1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.